Alpha-lipoic acid protects against hepatic ischemia-reperfusion injury in rats.
OBJECTIVE
To evaluate the protective effect of alpha-lipoic acid in reducing oxidative damage after severe hepatic ischemia/reperfusion (IR) injury.


METHODS
Wistar albino rats were subjected to 45 min of hepatic ischemia, followed by 60 min reperfusion period. Lipoic acid (100 mg/kg i.p.) was administered 15 min prior to ischemia and immediately before reperfusion period. At the end of the reperfusion period aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) activity, and cytokine, TNF-alpha and IL-1beta levels were determined in serum samples. Malondialdehyde (MDA), and glutathione (GSH) levels and myeloperoxidase (MPO) activity were determined in the liver tissue samples while formation of reactive oxygen species was monitored by using chemiluminescence (CL) technique with luminol and lucigenin probes. Tissues were also analyzed histologically.


RESULTS
Serum ALT, AST, and LDH activities and TNF-alpha and IL-1beta levels were elevated in the I/R group, while this increase was significantly lower in the group of animals treated concomitantly with lipoic acid. Hepatic GSH levels, significantly depressed by I/R, were elevated back to control levels in lipoic acid-treated I/R group. Furthermore, increases in tissue luminol and lucigenin CL, MDA levels and MPO activity due to I/R injury were reduced back to control levels with lipoic acid treatment.


CONCLUSIONS
Since lipoic acid administration alleviated the I/R-induced liver injury and improved the hepatic structure and function, it seems likely that lipoic acid with its antioxidant and oxidant-scavenging properties may be of potential therapeutic value in protecting the liver against oxidative injury due to ischemia-reperfusion.
Dulundu
Ender
E
Department of 5th Surgery, Haydarpasa Numune Educational and Research Hospital, Istanbul, Turkey.
Ozel
Yahya
Y
Topaloglu
Umit
U
Sehirli
Ozer
O
Ercan
Feriha
F
Gedik
Nursal
N
Sener
Goksel
G
D000166:Acridines / Q000378:metabolism; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D005978:Glutathione / Q000378:metabolism; D022781:Hepatocytes / Q000187:drug effects; D053583:Interleukin-1beta / Q000378:metabolism; D007770:L-Lactate Dehydrogenase / Q000097:blood; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D008165:Luminol / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008859:Microscopy, Polarization / Q000379:methods; D020556:Neutrophil Infiltration / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D008063:Thioctic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000166:Acridines; D000975:Antioxidants; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; C033472:10,10'-dimethyl-9,9'-biacridinium; D008315:Malondialdehyde; D008165:Luminol; D008063:Thioctic Acid; D007770:L-Lactate Dehydrogenase; D009195:Peroxidase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005978:Glutathione